Dr. Michael Donovan Joins Cellworks to Oversee Personalized Cancer Therapy Biosimulation in New CLIA-Certified Lab
Prominent academic and biotech leader Dr. Michael Donovan, PhD MD, has joined Cellworks as Laboratory Director to spearhead computational biosimulation efforts for delivering Personalized Therapy Decision Support reports within the newly registered CLIA lab.
- Prominent academic and biotech leader Dr. Michael Donovan, PhD MD, has joined Cellworks as Laboratory Director to spearhead computational biosimulation efforts for delivering Personalized Therapy Decision Support reports within the newly registered CLIA lab.
- This new facility signifies a major step forward in Cellworks’ aim to establish a novel transformation in Personalized Therapy Decision Support with an initial focus on delivering personalized therapy predictions for non-small cell lung cancer (NSCLC) patients.
- The Cellworks Platform coupled with its in silico Computational Biology Model (CBM) utilizes genomic aberrations from a patient’s cancer tumor to reveal how the tumor will respond to therapies.
- “We have an incredible opportunity to pioneer advancements in Personalized Therapy Biosimulation, starting with important breakthroughs for NSCLC patients.